Xenon Pharmaceuticals (XENE) Accounts Payables (2013 - 2026)

Xenon Pharmaceuticals (XENE) has 14 years of Accounts Payables data on file, last reported at $5.7 million in Q1 2026.

• Accounts Payables for Q1 2026 came in at $5.7 million, down 81.25% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.7 million (down 81.25% YoY), and the FY2025 annual result was $3.9 million, down 23.37% from the prior year.
• Accounts Payables grew to $5.7 million in Q1 2026 per XENE's latest filing, from $3.9 million in the prior quarter.
• Over five years, Accounts Payables peaked at $36.8 million in Q3 2025 and troughed at $1.7 million in Q1 2022.
• A 5-year average of $15.4 million and a median of $12.0 million in 2023 frame the typical range for Accounts Payables.
• The sharpest annual moves came in 2023 and 2026: Accounts Payables jumped 1183.73% in 2023, then plunged 81.25% in 2026.
• A 5-year view of Accounts Payables shows it stood at $8.5 million in 2022, then surged by 205.9% to $26.0 million in 2023, then tumbled by 80.48% to $5.1 million in 2024, then declined by 23.37% to $3.9 million in 2025, then jumped by 47.95% to $5.7 million in 2026.
• Business Quant data shows XENE's Accounts Payables at $5.7 million in Q1 2026, $3.9 million in Q4 2025, and $36.8 million in Q3 2025.